ABBV 838

Drug Profile

ABBV 838

Alternative Names: ABBV-838

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action CD319 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 01 Jun 2017 AbbVie terminates a phase-I/Ib trial in Multiple myeloma (Monotherapy, Combination therapy, Second-line therapy or greater) in USA, France, Germany, Spain (Parenteral) (NCT02462525)
  • 01 Jun 2017 AbbVie withdraws prior to enrolment a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (PO, Tablet) (NCT02951117)
  • 28 Oct 2016 AbbVie plans a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, France, Spain and Australia (IV, Infusion) (NCT02951117)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top